Treace Medical Concepts, Inc. (TMCI)

Compare

8.15

-0.24

(-2.86%)

At close: 4:00:00 PM EDT

8.15

0.00

(0.00%)

After hours: 4:05:07 PM EDT

Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as well as the first presentation of the MTA3D™ Adductoplasty® c

GlobeNewswire 4 days ago

TMCI
-2.86%
Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference

Expands market-leading position with new best-in-class bunion technologiesPONTE VEDRA, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced new technology innovations featured at the 2025 American College of Foot and Ankle Surgeon

GlobeNewswire 7 days ago

TMCI
-2.86%
John Treace Spends US$524k On Treace Medical Concepts Stock

Those following along with Treace Medical Concepts, Inc. ( NASDAQ:TMCI ) will no doubt be intrigued by the recent...

Simply Wall St. 23 days ago

TMCI
-2.86%
Treace Medical Concepts Full Year 2024 Earnings: EPS Beats Expectations

Treace Medical Concepts ( NASDAQ:TMCI ) Full Year 2024 Results Key Financial Results Revenue: US$209.4m (up 12% from FY...

Simply Wall St. last month

TMCI
-2.86%
Q4 2024 Treace Medical Concepts Inc Earnings Call

Q4 2024 Treace Medical Concepts Inc Earnings Call

Thomson Reuters StreetEvents last month

TMCI
-2.86%
Treace Medical Concepts Inc (TMCI) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Treace Medical Concepts Inc (TMCI) reports a 10.4% revenue increase and unveils new products, setting the stage for future growth despite a slight dip in gross margin.

GuruFocus.com last month

TMCI
-2.86%
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 66.67% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

TMCI
-2.86%
Treace Medical Concepts: Q4 Earnings Snapshot

The Ponte Vedra, Florida-based company said it had a loss of 1 cent per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 3 cents per share.

Associated Press Finance last month

TMCI
-2.86%
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results

PONTE VEDRA, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Revenue of $68.7 million in fourth quarter 2024 increased 10% over s

GlobeNewswire last month

TMCI
-2.86%
Insider Stock Buying Reaches US$7.31m On Treace Medical Concepts

Quite a few insiders have dramatically grown their holdings in Treace Medical Concepts, Inc. ( NASDAQ:TMCI ) over the...

Simply Wall St. last month

TMCI
-2.86%
Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management wil

GlobeNewswire last month

TMCI
-2.86%
Why Treace Medical Concepts (TMCI) Is Rallying Today

Treace Medical Concepts (TMCI) is jumping 7.5% after investment bank BTIG upgraded the shares to Buy from Neutral. Why BTIG Upgraded the Shares Treace provides technology that facilitates Lapiplasty bunion surgery and related midfoot deformities. The company recently introduced a new technique called the SpeedAkin™ Anatomic Compression Implant. The “implant broadens the procedural versatility of […]

Insider Monkey last month

TMCI
-2.86%
Treace Announces First Surgical Cases Utilizing the SpeedAkin™ Anatomic Compression Implant

PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing its SpeedAkin™ Anatomic Compression Implant. The SpeedAkin™ implant broadens the procedural versatility of Tre

GlobeNewswire last month

TMCI
-2.86%
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue of $68.4 million to $68.8 million in the fourth quarter of 2024

GlobeNewswire 2 months ago

TMCI
-2.86%
TMCI Stock May Gain From the Limited Release of the Percuplasty System

Treace Medical announces the limited market release of the Percuplasty Percutaneous 3D Bunion Correction System, targeting the in-demand bunion surgery market.

Zacks 2 months ago

TMCI
-2.86%
Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference

PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximat

GlobeNewswire 2 months ago

TMCI
-2.86%
Treace Expands Reach into High-Volume Osteotomy Market with Second MIS Osteotomy Platform, Percuplasty™ Percutaneous 3D Bunion Correction® Procedure

Positions Treace to Significantly Increase Share of Overall Bunion Market and Expand Surgeon Customer BasePONTE VEDRA, Fla., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the limited market release and first surgical cases utilizi

GlobeNewswire 2 months ago

TMCI
-2.86%
With 54% institutional ownership, Treace Medical Concepts, Inc. (NASDAQ:TMCI) is a favorite amongst the big guns

Key Insights Given the large stake in the stock by institutions, Treace Medical Concepts' stock price might be...

Simply Wall St. 3 months ago

TMCI
-2.86%
Treace Medical price target raised to $8.40 from $7 at Truist

Truist raised the firm’s price target on Treace Medical (TMCI) to $8.40 from $7 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance sh

TipRanks 3 months ago

TMCI
-2.86%
Treace Announces First Surgical Cases Utilizing the SpeedPlate™ MicroQuad™ Implant

PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad™ implants. The MicroQuad™ implant expands upon the broad utility of the SpeedPlate™ plat

GlobeNewswire 3 months ago

TMCI
-2.86%

Performance Overview

Return	TMCI	S&P 500 (^GSPC)
YTD	+9.54%	-4.23%
1-Year	-34.80%	+7.42%
3-Year	-58.21%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Treace Medical Concepts, Inc. (TMCI)

Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference

Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference

John Treace Spends US$524k On Treace Medical Concepts Stock

Treace Medical Concepts Full Year 2024 Earnings: EPS Beats Expectations

Q4 2024 Treace Medical Concepts Inc Earnings Call

Treace Medical Concepts Inc (TMCI) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates

Treace Medical Concepts: Q4 Earnings Snapshot

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results

Insider Stock Buying Reaches US$7.31m On Treace Medical Concepts

Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Why Treace Medical Concepts (TMCI) Is Rallying Today

Treace Announces First Surgical Cases Utilizing the SpeedAkin™ Anatomic Compression Implant

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue

TMCI Stock May Gain From the Limited Release of the Percuplasty System

Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference

Treace Expands Reach into High-Volume Osteotomy Market with Second MIS Osteotomy Platform, Percuplasty™ Percutaneous 3D Bunion Correction® Procedure

With 54% institutional ownership, Treace Medical Concepts, Inc. (NASDAQ:TMCI) is a favorite amongst the big guns

Treace Medical price target raised to $8.40 from $7 at Truist

Treace Announces First Surgical Cases Utilizing the SpeedPlate™ MicroQuad™ Implant

Performance Overview